

Supplementary Table 2. Medications at discharge in checklist and non-checklist group

	Checklist group	Non-checklist group	<i>p</i> value
Medication in all subtypes of heart failure	244	171	
RASI (ACEI, ARB, ARNI)	134 (54.9)	78 (45.6)	0.062
ACEI/ARB use	97 (39.8)	60 (35.1)	0.335
ARNI use	37 (15.2)	18 (10.5)	0.170
Beta-blockers use	165 (67.6)	87 (50.9)	0.001
MRA use	100 (41.0)	59 (34.5)	0.181
Ivabradine use	15 (6.2)	6 (3.5)	0.224
SGLT2 inhibitors	40 (16.4)	25 (14.7)	0.642
Among DM	26 (25.0)	20 (30.8)	0.412
Medication in HFrEF patients	131	75	
RASI (ACEI, ARB, ARNI)	87 (66.4)	44 (58.7)	0.266
ACEI/ARB use	53 (40.5)	26 (34.7)	0.411
ARNI use	34 (26.0)	18 (24.0)	0.756
Beta-blockers use	104 (79.4)	47 (62.7)	0.009
MRA use	64 (48.9)	33 (44.0)	0.502
Ivabradine use	14 (10.7)	6 (8.0)	0.531
SGLT2 inhibitors	30 (22.9)	13 (17.3)	0.344
Among DM	20 (30.8)	9 (26.5)	0.425
Anticoagulant or antiplatelet medication on HF patient with atrial fibrillation	100	58	
Anticoagulant	66 (66.7)	39 (69.6)	0.703
NOAC	52 (52.5)	32 (57.1)	0.579
Warfarin	14 (14.1)	7 (12.5)	0.774
Antiplatelet	10 (10.1)	4 (7.1)	0.537
Antiplatelet and anticoagulant	14 (14.1)	9 (16.1)	0.745
None	9 (9.1)	4 (7.1)	0.674
Number of GDMT and adequacy score			
Number of GDMT	2 (1–2)	1 (1–2)	< 0.001
Adequacy score 1	3 (2–5)	2 (1–4)	< 0.001
Adequacy score 2	3 (1–4)	2 (1–4)	0.003

Values are presented as median (interquartile range) or number (%).

RASI, renin-angiotensin system inhibitors; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor-neprilysin inhibitor; MRA, mineralocorticoid-receptor-antagonists; SGLT2, sodium-glucose cotransporter-2; DM, diabetes mellitus; HFrEF, heart failure with reduced ejection fraction; HF, heart failure; NOAC, non-vitamin K oral anticoagulants; GDMT, guideline-directed medical therapy.